N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,436 Superficial and Cutaneous Fungal Infections Among Drug-users in Northeast Region of Iran
Skin and Subcutaneous Tissue Fungal Infections
Primary: The Prevalence of Superficial and Cutaneous Fungal Infections Among Drug and Non-Drug Users — 73; 62 participants
Phase 3 N=121 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
Fungal Infection
Primary: Number of Participants With a Significant Drug-related Adverse Experience — 3; 6 Participants
N/A N=23 A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
Systemic Fungal Infections
Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants
Phase 3 N=88 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
Invasive Fungal Infections
Primary: Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14 — 60.5; 71.0 percentage of participants
Phase 2 N=20 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis
Primary: Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis
Phase 3 N=70 Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
N/A N=50 Spread of Dermatophytes Among Families
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates
Phase 3 N=55 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
Mycoses · Candidiasis · Aspergillosis
Primary: Maximum Plasma Itraconazole Concentration (Cmax) — 2.90; 2.30; 1.79; 9.20 mcg/ml
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Phase 3 N=240 The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Corneal Ulcer · Eye Infections, Fungal
Primary: Incidence of Perforation or Therapeutic Penetrating Keratoplasty — 0.0095562; 0.011204 New perforations or TPK/person-days — p=0.29
Phase 4 N=19 Study Evaluating the Effect of Jublia on Dermatophytomas
Onychomycosis · Dermatophytosis
Primary: Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO) — 19 Participants
N/A N=323 Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 4 N=73 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
Onychomycosis
Primary: Mycological Cure — 17; 28; 16; 13 Percentage of participants — p=<0.05
N/A N=116 An Observational Study of Fungal Biomarkers (MK-0000-089)
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Phase 3 N=40 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Onychomycosis
Primary: Primary Endpoint - Efficacy — 4 Participants
Phase 2 N=112 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Phase 2 N=118 Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
Phase 4 N=132 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
Onychomycosis, Toe
Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants
Phase 3 N=204 A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Invasive Candidiasis
Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants
Phase 3 N=518 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants
Phase 3 N=526 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…
Phase 4 N=71 An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
Pulmonary Fungal Infection
Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants